Revolune Launches Multiplex Immunofluorescence Reagents, Partners with MindPeak for AI-Powered Spatial Biology Workflow
核心洞察
Revolune (搜索) announced commercial availability of its multiplex immunofluorescence reagents on June 15, 2026, transitioning from early access to full market deployment for spatial biology workflows.
The reagents enable visualization of multiple protein biomarkers in intact tissues, addressing challenges of complex assays and lengthy protocols in translational research.
Revolune (搜索) and MindPeak (搜索) will showcase an integrated workflow at AACR 2026 combining multiplex IF reagents with AI-driven pathology analysis for automated biomarker quantification.
Revolune (搜索) GmbH has announced the commercial availability of its multiplex immunofluorescence (mIF) reagents as of June 15, 2026, marking a transition from an early access phase to broader market deployment. The launch positions the company to support scalable and reproducible spatial biology workflows across translational research, biopharmaceutical applications, and biomarker discovery.
The reagent platform is designed to enable visualization of multiple protein biomarkers in intact tissues, directly addressing persistent challenges in the field—namely complex assays and lengthy protocols that have historically limited routine adoption of multiplex immunofluorescence. Revolune (搜索) aims to make these techniques accessible for everyday laboratory use.
"We developed our reagents to simplify what has traditionally been a technically demanding process," said Florian Leiss, CEO of Revolune (搜索). "By reducing complexity, we hope to accelerate the pace of spatial biology research."
Early Access Program Informs Commercial Strategy
The commercial rollout builds on feedback gathered from Revolune (搜索)'s early access program, which engaged more than 30 laboratories. This input helped refine the reagent platform ahead of full market availability. Initial offerings are targeted at applications in oncology, translational medicine, and biomarker development.
To drive global adoption, Revolune (搜索) has appointed Adrian Arechiga as Chief Commercial Officer, tasking him with leading the company's commercial strategy.
Integrated Workflow with MindPeak (搜索) at AACR 2026
In parallel with the commercial launch, Revolune (搜索) and MindPeak (搜索)—a leader in AI-powered pathology analysis—announced they will jointly exhibit at the American Association for Cancer Research (AACR) Annual Meeting 2026. The companies will present an integrated workflow that combines Revolune's multiplex IF reagents with MindPeak's advanced image analysis solutions.
The combined approach aims to streamline the entire spatial biology pipeline, from tissue staining through to data interpretation. MindPeak (搜索)'s AI-driven pathology software enables automated analysis of multiplex imaging data, supporting quantitative biomarker assessment and spatial interpretation across complex tissue samples.
"Spatial biology requires both robust experimental workflows and reliable data interpretation," said Leiss. "By combining Revolune (搜索)'s multiplex IF chemistry with MindPeak (搜索)'s powerful AI-based analysis capabilities, we can help researchers simplify the path from tissue sample to actionable spatial insight."
Felix Faber, CEO of MindPeak (搜索), echoed this sentiment: "We are excited to collaborate with Revolune (搜索) to support researchers working with multiplex tissue data. Together we aim to reduce the barriers that often slow adoption of spatial biology workflows."
Addressing Unmet Needs in Spatial Biology
Multiplex immunofluorescence has become an increasingly important tool for understanding tumor biology, immune interactions, and the spatial context of biomarkers. However, many existing workflows remain technically complex and difficult to scale, creating bottlenecks in both academic and industry settings.
The Revolune (搜索)-MindPeak (搜索) partnership seeks to address these limitations by offering a more integrated and accessible workflow—from staining through to analysis—that can support translational cancer research and biomarker discovery efforts. Attendees at AACR 2026 can explore the combined workflow at booth 1660.